These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22075465)

  • 41. Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
    Kobayashi T; Tomomatsu J; Fukada I; Shibayama T; Teruya N; Ito Y; Iwase T; Ohno S; Takahashi S
    BMC Cancer; 2016 Jul; 16():404. PubMed ID: 27389013
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
    Falco I; Stragliotto S
    Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
    Fabi A; Moscetti L; Ciccarese M; Caramanti M; Salesi N; La Verde N; Russillo M; Generali D; Scandurra G; Vari S; Pacetti U; Cognetti F; Giannarelli D
    Future Oncol; 2015; 11(3):431-8. PubMed ID: 25675124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
    Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
    Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
    Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Eribulin long-term response and rechallenge: report of two clinical cases.
    Barbieri E; Rubino D; Hakim R; Fini A; Lenzi M; Zamagni C
    Future Oncol; 2017 Apr; 13(11s):35-43. PubMed ID: 28481188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
    Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
    Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Complex synthesis yields breast-cancer therapy.
    Ledford H
    Nature; 2010 Dec; 468(7324):608-9. PubMed ID: 21124423
    [No Abstract]   [Full Text] [Related]  

  • 52. The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
    Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Fujita H; Takashima T; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
    Anticancer Res; 2019 Aug; 39(8):4031-4041. PubMed ID: 31366485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
    Donoghue M; Lemery SJ; Yuan W; He K; Sridhara R; Shord S; Zhao H; Marathe A; Kotch L; Jee J; Wang Y; Zhou L; Adams WM; Jarral V; Pilaro A; Lostritto R; Gootenberg JE; Keegan P; Pazdur R
    Clin Cancer Res; 2012 Mar; 18(6):1496-505. PubMed ID: 22282463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
    Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
    Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eribulin mesylate in patients with refractory cancers: a Phase I study.
    Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
    Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.
    Macpherson IR; He Y; Palmieri C
    Breast Cancer Res; 2021 Mar; 23(1):33. PubMed ID: 33736675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Eribulin targets a ch-TOG-dependent directed migration of cancer cells.
    Chanez B; Gonçalves A; Badache A; Verdier-Pinard P
    Oncotarget; 2015 Dec; 6(39):41667-78. PubMed ID: 26497677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eribulin in advanced breast cancer: safety, efficacy and new perspectives.
    Garrone O; Miraglio E; Vandone AM; Vanella P; Lingua D; Merlano MC
    Future Oncol; 2017 Dec; 13(30):2759-2769. PubMed ID: 29219017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin.
    La Verde N; Piva S; Ganzinelli M; Farina G; Gherardi G; Girelli S; Bramati A; Del Re L; Damia G
    Future Oncol; 2013 Nov; 9(11):1703-9. PubMed ID: 24156329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.
    Thara E; Gitlitz BJ
    Future Oncol; 2014 Oct; 10(12):1913-24. PubMed ID: 25386810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.